

## Special Issue

# In Memoriam of Joy Dorothy Ann Delhanty

### Message from the Guest Editors

Joy Delhanty was a leading cytogeneticist and pioneer of Preimplantation Genetic Testing (PGT). She was an academic at Univeristy College London for the entirety of her career and most recently as Emeritus Professor. Sadly, she passed away in September 2021, and her last words were apparently “make sure you get this published.” Joy and her lab are credited with performing the world’s first cytogenetic PGT, in describing the world’s first human triploid, Robertsonian translocations as a cause for Down syndrome and a body of seminal work on cancer mutations and embryo mosaicism. To honour her last wish, this Special Issue, comprising largely of work from her many former students, celebrates her life with a selection of articles on genetics with a specific emphasis in early human development.

---

### Guest Editors

Prof. Dr. Darren Griffin

School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK

Dr. Sioban Sen Gupta

EGA Institute for Women’s Health, University College London, London, UK

---

### Deadline for manuscript submissions

closed (1 February 2023)



## DNA

---

an Open Access Journal  
by MDPI

---

Tracked for Impact Factor



[mdpi.com/si/102180](https://mdpi.com/si/102180)

*DNA*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[dna@mdpi.com](mailto:dna@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[dna](https://mdpi.com/journal/dna)





# DNA

---

an Open Access Journal  
by MDPI

---

Tracked for Impact Factor



[mdpi.com/journal/  
dna](https://mdpi.com/journal/dna)



## About the Journal

### Message from the Editor-in-Chief

Since the first human and mouse genome sequence assemblies over 20 years ago, hundreds of species are now complete, impacting on diagnostics, medicine, agriculture and the environment. Taking a “sequence to consequence” and “structure to nature” philosophy with clearly written, accessible manuscripts, *DNA* will publish novel research findings, reviews and communications in DNA-related technologies, genome structures, DNA-targeted therapies, bioinformatics and cytogenomics. As pioneers in DNA technology, we owe it to the next generation to take the lead in carving a new path that the enigmatic double helix at the core of our essence shows us. We look forward to hearing from you and distributing your insights to the community.

---

### Editor-in-Chief

Prof. Dr. Yves Pommier

Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD 20892, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within ESCI (Web of Science) and other databases.

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 36 days after submission; acceptance to publication is undertaken in 14.7 days (median values for papers published in this journal in the second half of 2025).